The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
复制标题
DOI：
10.1056/nejmoa030656
复制
发表时间：
2003-12-18
影响因子：
158.5
通讯作者：
Grossman, E
中科院分区：
文献类型：
--
作者：
McConnell, JD;Roehrborn, CG;Grossman, E
背景技术背景：良性前列腺增生通常用α-肾上腺素能受体拮抗剂（α-阻断剂）或5（α）-还原酶抑制剂治疗。这些药物单独或联合使用对临床进展风险的长期影响尚不清楚。方法：我们进行了一项长期、双盲试验（平均随访4.5年），共3047名男性，比较安慰剂、多沙唑嗪、非那肽和联合治疗对良性前列腺增生临床进展的影响。多沙唑嗪显著降低了总体临床进展的风险（定义为美国泌尿外科协会症状评分高于基线至少4分，急性尿潴留，尿失禁，肾功能不全或复发性尿路感染）（风险降低39%，P
BACKGROUND: Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5(alpha)-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.METHODS: We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.RESULTS: The risk of overall clinical progression -- defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection -- was significantly reduced by doxazosin (39 percent risk reduction, P